All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

December 8th 2024

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Oral Revumenib-Based Combo Produces Responses in R/R AML

December 8th 2024

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma

December 8th 2024

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.

Revumenib Displays Activity in Relapsed/Refractory KMT2A+ Acute Leukemias

December 8th 2024

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Recapping the Latest in AML With Dr Eunice Wang

December 8th 2024

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Smoking May Increase Genetic Mutations, Disease Progression in MDS

December 7th 2024

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL

December 7th 2024

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Targeting PIK3CA With Allosteric Inhibitors Is Promising New Approach in Breast Cancer

December 6th 2024

Felipe Batalini, MD, details how targeting PIK3CA is evolving in breast cancer as new allosteric inhibitors have emerged and showed promising safety/efficacy.

JAK Inhibitors Remain Central to Advancing Care in Myelofibrosis

December 6th 2024

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis and how the use of this class of agents may evolve.

NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC

December 6th 2024

Cathy Eng, MD, FACP, FASCO, shares insights on biomarker testing and sequencing strategies for patients with colorectal cancer.

Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia

December 6th 2024

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.

AdAPT-001 Gets FDA Fast Track Designation in Recurrent/Refractory Soft Tissue Sarcoma

December 6th 2024

AdAPT-001 plus nivolumab or atezolizumab has received fast track designation from the FDA in recurrent/refractory soft tissue sarcoma.

RP1 and Other Oncolytic Viruses Could Pave a New Treatment Pathway in Advanced Melanoma

December 6th 2024

Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.

FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer

December 6th 2024

The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.

Fox Chase Cancer Center’s Department of Clinical Genetics Expands Reach With Genetic Counseling and High-Risk Clinical Services at Chestnut Hill Hospital

December 6th 2024

Fox Chase Cancer Center is offering genetic counseling for those considered at high risk for breast cancer at Temple Health - Chestnut Hill Hospital.